Healthcare entity

Extensive-stage small cell lung cancer (ES-SCLC)

Company

market-trends is the sole category represented across all 1 tracked stories. Chemotherapy-induced myelosuppression (CIM) is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Their average consequence score of 6 sits level with the 6 recorded across the beat in that window.

Last mentioned: Jul 27, 2026

Entity pulse

Recent coverage · Extensive-stage small cell lung cancer (ES-SCLC)

1 story
6 avg impact
100% positive
0% negative

Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.

  • 100% positive

Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.

What the coverage shows about Extensive-stage small cell lung cancer (ES-SCLC)

market-trends is the sole category represented across all 1 tracked stories. Chemotherapy-induced myelosuppression (CIM) is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Their average consequence score of 6 sits level with the 6 recorded across the beat in that window. Source depth averages 2 original sources per story, versus 2.2 across the same-window beat baseline. We currently track 1 Healthcare story that mention Extensive-stage small cell lung cancer (ES-SCLC), all published on July 27, 2026.

Stories tracked
1
Sources per story
2

Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 23 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.

Coverage cohort

Appears alongside

Other entities that clear the same relevance threshold in stories also covering Extensive-stage small cell lung cancer (ES-SCLC). Shared-story counts are live from our verified record — not editorial picks.

Timeline

  1. Partnership Announcement

    Menarini Asia-Pacific and Pharmacosmos announce exclusive licensing and distribution agreement for Cosela in 11 APAC markets.

Stories mentioning Extensive-stage small cell lung cancer (ES-SCLC) 1

Extensive-stage small cell lung cancer (ES-SCLC) is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.

See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.